The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease
Status:
Unknown status
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
1. Stains have demonstrated consistent benefits to reduce cardiovascular events in several
primary and secondary prevention trials. The suppression of plaque progression or
regression may be a part of mechanism of clinical benefit. The intravascular ultrasound
studies demonstrated that intensive statin therapy can regress or inhibit the
progression of coronary atherosclerosis.
2. Unregulated renin-angiotensin system is important in the pathogenesis of cardiovascular
disease. Angiotensin receptor antagonists (ARB) have been reported to improve clinical
outcomes in patients with heart failure, left ventricular dysfunction, myocardial
infarction, and high-risk patients. Several small studies showed that ARBs were
effective to inhibit the progression of coronary atherosclerosis by intravascular
ultrasound examination.
3. The combined therapy with statins and ARBs may be additive or synergistic effects on the
atherosclerosis regression as well as to improve endothelial dysfunction and insulin
resistance in addition to lowering cholesterol levels and blood pressure when compared
with either monotherapy in patients.
4. Serial computed tomography angiography (CTA) can be utilized to assess the effect of
treatment on coronary plaque morphology. In addition to the assessment of luminal
stenosis, CTA also allows characterization of plaque morphology.